Source - Alliance News

The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC’s commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud’s management. The first order, on track to be delivered during the second quarter of 2024, will generate around £2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: ‘As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera’s revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company’s revolutionary skincare range and its partnership with Marionnaud.’

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area’s shallow structures at ‘indicative prices potentially significantly greater than its current carrying value’. Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. ‘We believe this heightened level of corporate interest in BNG’s producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect,’ the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of £243,534 from a profit of £326,021 a year earlier. Revenue falls to £6.6 million from £7.1 million, while administrative expenses rise to £1.7 million from £1.2 million. Expects full-year revenue of no less than £19 million compared to £20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: ‘With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year’s financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders.’

----------

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Caspian Sunrise PLC (CASP)

+0.05p (+1.56%)
delayed 15:57PM

Immupharma PLC (IMM)

-0.03p (-1.12%)
delayed 16:30PM

Aeorema Communications PLC (AEO)

0p (0.00%)
delayed 15:57PM